JP6529440B2 - 膵内分泌細胞への分化のためのヒト多能性細胞の懸濁及びクラスタリング - Google Patents
膵内分泌細胞への分化のためのヒト多能性細胞の懸濁及びクラスタリング Download PDFInfo
- Publication number
- JP6529440B2 JP6529440B2 JP2015550826A JP2015550826A JP6529440B2 JP 6529440 B2 JP6529440 B2 JP 6529440B2 JP 2015550826 A JP2015550826 A JP 2015550826A JP 2015550826 A JP2015550826 A JP 2015550826A JP 6529440 B2 JP6529440 B2 JP 6529440B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- differentiation
- stage
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004027 cell Anatomy 0.000 title claims description 1011
- 230000004069 differentiation Effects 0.000 title description 301
- 239000000725 suspension Substances 0.000 title description 69
- 230000009996 pancreatic endocrine effect Effects 0.000 title description 20
- 210000003890 endocrine cell Anatomy 0.000 title description 18
- 230000014509 gene expression Effects 0.000 claims description 370
- 239000002609 medium Substances 0.000 claims description 208
- 238000000034 method Methods 0.000 claims description 141
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 124
- 108090000623 proteins and genes Proteins 0.000 claims description 124
- 238000004114 suspension culture Methods 0.000 claims description 108
- 210000001900 endoderm Anatomy 0.000 claims description 97
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 79
- 239000008103 glucose Substances 0.000 claims description 77
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 70
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 69
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 48
- 230000001965 increasing effect Effects 0.000 claims description 45
- 108010023082 activin A Proteins 0.000 claims description 38
- 239000001963 growth medium Substances 0.000 claims description 31
- 102000004190 Enzymes Human genes 0.000 claims description 27
- 108090000790 Enzymes Proteins 0.000 claims description 27
- 101150068520 wnt3a gene Proteins 0.000 claims description 24
- 239000002738 chelating agent Substances 0.000 claims description 17
- 238000012258 culturing Methods 0.000 claims description 15
- 230000022131 cell cycle Effects 0.000 claims description 12
- 210000004039 endoderm cell Anatomy 0.000 claims description 11
- 102000043168 TGF-beta family Human genes 0.000 claims description 6
- 108091085018 TGF-beta family Proteins 0.000 claims description 6
- 101150004578 gdf-8 gene Proteins 0.000 claims description 5
- 230000035519 G0 Phase Effects 0.000 claims description 2
- 230000010190 G1 phase Effects 0.000 claims description 2
- 108700013515 Wnt3A Proteins 0.000 claims description 2
- 102000044880 Wnt3A Human genes 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims 7
- SCVDQROBPYCNAO-UHFFFAOYSA-N aniline;pyrido[3,2-d]triazine Chemical compound NC1=CC=CC=C1.C1=NN=NC2=CC=CN=C21 SCVDQROBPYCNAO-UHFFFAOYSA-N 0.000 claims 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 4
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 2
- 230000004931 aggregating effect Effects 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 102
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 102
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 78
- 210000000130 stem cell Anatomy 0.000 description 63
- 230000008859 change Effects 0.000 description 54
- 238000000684 flow cytometry Methods 0.000 description 52
- -1 GCG Proteins 0.000 description 49
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 49
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 49
- 230000000977 initiatory effect Effects 0.000 description 49
- 210000001519 tissue Anatomy 0.000 description 47
- 102100028098 Homeobox protein Nkx-6.1 Human genes 0.000 description 40
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 40
- 101000578258 Homo sapiens Homeobox protein Nkx-6.2 Proteins 0.000 description 39
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 39
- 239000003550 marker Substances 0.000 description 36
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 35
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 35
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 35
- 230000008569 process Effects 0.000 description 35
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 34
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 30
- 102100031671 Homeobox protein CDX-2 Human genes 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 28
- 102000024905 CD99 Human genes 0.000 description 27
- 108060001253 CD99 Proteins 0.000 description 27
- 239000011521 glass Substances 0.000 description 27
- 238000011081 inoculation Methods 0.000 description 27
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 26
- 239000006285 cell suspension Substances 0.000 description 26
- 238000002513 implantation Methods 0.000 description 25
- 102100027886 Homeobox protein Nkx-2.2 Human genes 0.000 description 24
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 24
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 24
- 238000004115 adherent culture Methods 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 24
- 239000000523 sample Substances 0.000 description 24
- 108010075254 C-Peptide Proteins 0.000 description 23
- 206010012601 diabetes mellitus Diseases 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 101100518002 Danio rerio nkx2.2a gene Proteins 0.000 description 22
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 22
- 101100460496 Homo sapiens NKX2-2 gene Proteins 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 22
- 108010056852 Myostatin Proteins 0.000 description 22
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 22
- 102100025745 Cerberus Human genes 0.000 description 21
- 241000202252 Cerberus Species 0.000 description 21
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 21
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 21
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 21
- 101100074833 Lotus japonicus CERBERUS gene Proteins 0.000 description 21
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 21
- 108010076089 accutase Proteins 0.000 description 21
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 19
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 19
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
- 102100021382 Transcription factor GATA-6 Human genes 0.000 description 19
- 238000003491 array Methods 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 239000001301 oxygen Substances 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 19
- 239000002243 precursor Substances 0.000 description 19
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 18
- 239000007640 basal medium Substances 0.000 description 18
- 239000003590 rho kinase inhibitor Substances 0.000 description 18
- 102100024208 Homeobox protein MIXL1 Human genes 0.000 description 17
- 102100038146 Homeobox protein goosecoid Human genes 0.000 description 17
- 239000011324 bead Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 description 16
- 101000878124 Homo sapiens Fibroblast growth factor 17 Proteins 0.000 description 16
- 101710123134 Ice-binding protein Proteins 0.000 description 16
- 101710082837 Ice-structuring protein Proteins 0.000 description 16
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 16
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 16
- 101001052462 Homo sapiens Homeobox protein MIXL1 Proteins 0.000 description 15
- 101001032602 Homo sapiens Homeobox protein goosecoid Proteins 0.000 description 15
- 101000576323 Homo sapiens Motor neuron and pancreas homeobox protein 1 Proteins 0.000 description 15
- 102100025170 Motor neuron and pancreas homeobox protein 1 Human genes 0.000 description 15
- 101150079937 NEUROD1 gene Proteins 0.000 description 15
- 102100034593 Tripartite motif-containing protein 26 Human genes 0.000 description 15
- 229910002091 carbon monoxide Inorganic materials 0.000 description 15
- 230000003068 static effect Effects 0.000 description 15
- 102100021022 Gastrin Human genes 0.000 description 14
- 101001002317 Homo sapiens Gastrin Proteins 0.000 description 14
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 14
- 102100037506 Paired box protein Pax-6 Human genes 0.000 description 14
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 14
- 230000024245 cell differentiation Effects 0.000 description 14
- 210000003981 ectoderm Anatomy 0.000 description 14
- 239000007789 gas Substances 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 238000012546 transfer Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000002775 capsule Substances 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 210000000496 pancreas Anatomy 0.000 description 13
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 13
- 108010007718 Chromogranins Proteins 0.000 description 12
- 102000007345 Chromogranins Human genes 0.000 description 12
- 102000040945 Transcription factor Human genes 0.000 description 12
- 108091023040 Transcription factor Proteins 0.000 description 12
- 230000002596 correlated effect Effects 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 101000923091 Danio rerio Aristaless-related homeobox protein Proteins 0.000 description 11
- 102100030751 Eomesodermin homolog Human genes 0.000 description 11
- 102100031470 Homeobox protein ARX Human genes 0.000 description 11
- 101000923090 Homo sapiens Homeobox protein ARX Proteins 0.000 description 11
- 101000613495 Homo sapiens Paired box protein Pax-4 Proteins 0.000 description 11
- 102100040909 Paired box protein Pax-4 Human genes 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 230000002572 peristaltic effect Effects 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 230000007704 transition Effects 0.000 description 11
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 description 10
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 10
- 102100023915 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 102100038553 Neurogenin-3 Human genes 0.000 description 10
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000010494 dissociation reaction Methods 0.000 description 10
- 230000005593 dissociations Effects 0.000 description 10
- 239000012737 fresh medium Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 210000003716 mesoderm Anatomy 0.000 description 10
- 229960001052 streptozocin Drugs 0.000 description 10
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 9
- 101150068639 Hnf4a gene Proteins 0.000 description 9
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 9
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 9
- 101001069749 Homo sapiens Prospero homeobox protein 1 Proteins 0.000 description 9
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 9
- 108700020297 NeuroD Proteins 0.000 description 9
- 102100033880 Prospero homeobox protein 1 Human genes 0.000 description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 239000004033 plastic Substances 0.000 description 9
- 229920003023 plastic Polymers 0.000 description 9
- 229930002330 retinoic acid Natural products 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 101001021503 Homo sapiens Hematopoietically-expressed homeobox protein HHEX Proteins 0.000 description 8
- 101000738523 Homo sapiens Pancreas transcription factor 1 subunit alpha Proteins 0.000 description 8
- 102100037878 Pancreas transcription factor 1 subunit alpha Human genes 0.000 description 8
- 108010007093 dispase Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 102100035961 Hematopoietically-expressed homeobox protein HHEX Human genes 0.000 description 7
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 7
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 7
- 238000013019 agitation Methods 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000035800 maturation Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102000035092 Neutral proteases Human genes 0.000 description 6
- 108091005507 Neutral proteases Proteins 0.000 description 6
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 6
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 210000001654 germ layer Anatomy 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000013411 master cell bank Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000010257 thawing Methods 0.000 description 6
- 229960001727 tretinoin Drugs 0.000 description 6
- 101150084750 1 gene Proteins 0.000 description 5
- 108090000145 Bacillolysin Proteins 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- 102100036364 Cadherin-2 Human genes 0.000 description 5
- 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 description 5
- 101000979190 Homo sapiens Transcription factor MafB Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 102100023234 Transcription factor MafB Human genes 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002480 immunoprotective effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 210000003954 umbilical cord Anatomy 0.000 description 5
- 102100036537 von Willebrand factor Human genes 0.000 description 5
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 4
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 4
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 4
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 4
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- 102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 description 4
- 102100030634 Homeobox protein OTX2 Human genes 0.000 description 4
- 101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 description 4
- 101000584400 Homo sapiens Homeobox protein OTX2 Proteins 0.000 description 4
- 101000598781 Homo sapiens Oxidative stress-responsive serine-rich protein 1 Proteins 0.000 description 4
- 101000613717 Homo sapiens Protein odd-skipped-related 1 Proteins 0.000 description 4
- 101001098464 Homo sapiens Serine/threonine-protein kinase OSR1 Proteins 0.000 description 4
- 101000642523 Homo sapiens Transcription factor SOX-7 Proteins 0.000 description 4
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 4
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 description 4
- 238000010222 PCR analysis Methods 0.000 description 4
- 102100040551 Protein odd-skipped-related 1 Human genes 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- 102100036730 Transcription factor SOX-7 Human genes 0.000 description 4
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 4
- 210000004381 amniotic fluid Anatomy 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003366 colagenolytic effect Effects 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 238000005138 cryopreservation Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000002064 heart cell Anatomy 0.000 description 4
- 239000013029 homogenous suspension Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000003061 neural cell Anatomy 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 230000015031 pancreas development Effects 0.000 description 4
- 230000001776 parthenogenetic effect Effects 0.000 description 4
- 238000002135 phase contrast microscopy Methods 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- WOLVEMPZUIFSII-IHHOKICGSA-N (2e,4e)-n-[(2s,5s)-5-(hydroxymethyl)-1-methyl-3-oxo-2-propan-2-yl-2,4,5,6-tetrahydro-1,4-benzodiazocin-8-yl]-5-[4-(trifluoromethyl)phenyl]penta-2,4-dienamide Chemical compound CN([C@H](C(N[C@H](CO)CC1=C2)=O)C(C)C)C1=CC=C2NC(=O)\C=C\C=C\C1=CC=C(C(F)(F)F)C=C1 WOLVEMPZUIFSII-IHHOKICGSA-N 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 3
- 101100046776 Arabidopsis thaliana TPPB gene Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 102100037060 Forkhead box protein D3 Human genes 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 102100023855 Heart- and neural crest derivatives-expressed protein 1 Human genes 0.000 description 3
- 101001029308 Homo sapiens Forkhead box protein D3 Proteins 0.000 description 3
- 101000905239 Homo sapiens Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 description 3
- 101000701142 Homo sapiens Transcription factor ATOH1 Proteins 0.000 description 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 102000004874 Synaptophysin Human genes 0.000 description 3
- 108090001076 Synaptophysin Proteins 0.000 description 3
- 101150050863 T gene Proteins 0.000 description 3
- 102100029373 Transcription factor ATOH1 Human genes 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 102000052549 Wnt-3 Human genes 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 208000036815 beta tubulin Diseases 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012595 freezing medium Substances 0.000 description 3
- 230000007045 gastrulation Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 0 Cc1cc(IC(CC2)CCN2ICC(N*CCc2cc(C3=C(C4)C4C(N4)=IC=N3)cnc2)=[U])cc4c1 Chemical compound Cc1cc(IC(CC2)CCN2ICC(N*CCc2cc(C3=C(C4)C4C(N4)=IC=N3)cnc2)=[U])cc4c1 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 101150075625 Gsc gene Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000632186 Homo sapiens Homeobox protein Nkx-2.2 Proteins 0.000 description 2
- 101100345674 Homo sapiens MIXL1 gene Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 101100011750 Mus musculus Hsp90b1 gene Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 101150111723 PDX1 gene Proteins 0.000 description 2
- 102100026844 Pancreatic prohormone Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 101150045640 VWF gene Proteins 0.000 description 2
- 101150068762 WNT-3 gene Proteins 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 210000002242 embryoid body Anatomy 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012092 media component Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000020925 non fasting Nutrition 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000035440 response to pH Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 101150117196 tra-1 gene Proteins 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- RHUJMHOIQBDFQR-UHFFFAOYSA-N 2-[[3-(2-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound COC1=CC=CC=C1N1C(=O)C(SCC2)=C2N=C1SCC(=O)NC1=NC2=CC=C(C)C=C2S1 RHUJMHOIQBDFQR-UHFFFAOYSA-N 0.000 description 1
- JOHJLWCTEGQDQB-UHFFFAOYSA-N 2-pyridin-4-ylpyrazolo[1,5-a]pyrimidine Chemical compound N=1N2C=CC=NC2=CC=1C1=CC=NC=C1 JOHJLWCTEGQDQB-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 101800001318 Capsid protein VP4 Proteins 0.000 description 1
- 101710010675 Cerberus Proteins 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150092314 EOMES gene Proteins 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 101150043457 Fgf4 gene Proteins 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000038624 GSKs Human genes 0.000 description 1
- 102100039290 Gap junction gamma-1 protein Human genes 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010087745 Hepatocyte Nuclear Factor 3-beta Proteins 0.000 description 1
- 102000009094 Hepatocyte Nuclear Factor 3-beta Human genes 0.000 description 1
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 102100031672 Homeobox protein CDX-1 Human genes 0.000 description 1
- 101000693913 Homo sapiens Albumin Proteins 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101100445363 Homo sapiens EOMES gene Proteins 0.000 description 1
- 101001065295 Homo sapiens Fas-binding factor 1 Proteins 0.000 description 1
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 1
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 1
- 101000777808 Homo sapiens Homeobox protein CDX-1 Proteins 0.000 description 1
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
- 101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 1
- 101000954762 Homo sapiens Proto-oncogene Wnt-3 Proteins 0.000 description 1
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 1
- 101000979205 Homo sapiens Transcription factor MafA Proteins 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 1
- 101000976653 Homo sapiens Zinc finger protein ZIC 1 Proteins 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 102100032132 Neuroendocrine convertase 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000052651 Pancreatic hormone Human genes 0.000 description 1
- 101800001268 Pancreatic hormone Proteins 0.000 description 1
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100023237 Transcription factor MafA Human genes 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100023497 Zinc finger protein ZIC 1 Human genes 0.000 description 1
- QRSFFHRCBYCWBS-UHFFFAOYSA-N [O].[O] Chemical compound [O].[O] QRSFFHRCBYCWBS-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 101150055484 cer1 gene Proteins 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 108010015426 connexin 45 Proteins 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 101150003286 gata4 gene Proteins 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000000829 induction skull melting Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- OGQSCIYDJSNCMY-UHFFFAOYSA-H iron(3+);methyl-dioxido-oxo-$l^{5}-arsane Chemical compound [Fe+3].[Fe+3].C[As]([O-])([O-])=O.C[As]([O-])([O-])=O.C[As]([O-])([O-])=O OGQSCIYDJSNCMY-UHFFFAOYSA-H 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000009753 muscle formation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 229940032957 pancreatic hormone Drugs 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000007261 regionalization Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/19—Growth and differentiation factors [GDF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2531/00—Microcarriers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本出願は、米国仮特許第61/747,799号(2012年12月31日出願)及び米国仮特許第61/962,158号(2013年11月1日)に対する優先権を主張し、これらの出願の両方は、その全体が参照によって組み込まれる。
本発明は、凝集した細胞クラスタにおいて、内胚葉前駆細胞、膵内分泌細胞、中胚葉細胞、又は外胚葉細胞への分化のための多能性を維持する、胚性幹細胞及び他の多能性細胞を調製することを含む、細胞分化の分野にある。一態様では、本発明は、多能性幹細胞のクラスタを生成し、膵臓内胚葉、膵内分泌前駆細胞、及び単一ホルモン膵内分泌細胞への分化のために、懸濁培養系内でそれらを維持する方法を開示する。
幹細胞は、単一細胞レベルでの自己再生能及び分化能の両方によって定義される未分化細胞である。幹細胞は、自己再生前駆細胞、非再生性前駆細胞、及び最終分化細胞を含む子孫細胞を産生することができる。幹細胞はまた、複数の胚葉(内胚葉、中胚葉、及び外胚葉)から様々な細胞系統の機能性細胞へと生体外で分化するそれらの能力を特徴とする。幹細胞は、移植後に複数の胚葉の組織を生じさせ、胚盤胞に注入後、実質的に(全てではないとしても)ほとんどの組織に寄与する。
多能性幹細胞は、指定されたTRA−1−60及びTRA−1−81抗体のうちの1つ以上を発現し得る(Thomson et al.1998,Science 282:1145〜1147)。生体外での多能性幹細胞の分化は、TRA−1−60及びTRA−1−81発現の損失をもたらす。未分化の多能性幹細胞は、典型的に、アルカリホスファターゼ活性を有し、これは、製造業者(Vector Laboratories(CA,USA))により説明されているように、細胞を4%のパラホルムアルデヒドで固定し、その後基質としてVector(登録商標)Redを使用して現像することにより検出され得る。未分化の多能性幹細胞はまた、RT−PCRにより検出されるように、典型的には、OCT4及びTERTも発現する。
本発明の方法において、任意の多能性幹細胞が使用され得る。使用され得る多能性幹細胞の例示的な型は、典型的には、妊娠約10〜12週よりも前であるが、必須ではない、妊娠中の任意の時期に採取した前胚性組織(例えば、胚盤胞など)、胚性組織、又は胎児組織などを含む、妊娠後に形成される組織に由来する多能性細胞の樹立株を含む。非限定的な例は、ヒト胚性幹細胞(hESCs)又はヒト胚生殖細胞の樹立株であり、例えば、ヒト胚性幹細胞株H1、H7、及びH9(WiCell Research Institute(Madison,WI,USA))などである。フィーダー細胞の不在下で既に培養された多能性幹細胞集団から採取した細胞も好適である。
多能性幹細胞の増大
本発明は、以下に記載される実施形態のいくつかにおいて、幹細胞の単離及び培養、特に動的懸濁培養系において多能性を保持する幹細胞クラスタの培養に関する。多能性細胞クラスタは、分化して、機能的β細胞を産生し得る。
ものとする。本発明を以下の実施例によって更に説明するが、本発明はこれらの実施例に
より限定されるものではない。
本出願は、例えば以下の発明を提供する。
[1] 三次元の細胞クラスタを産生する方法であって、
a.平面接着培養系で多能性幹細胞を成長させる工程と、
b.前記多能性幹細胞を凝集した細胞クラスタに増大させる工程と、
c.酵素又はキレート剤を使用して、前記多能性幹細胞のクラスタを、前記平面接着培養系から動的懸濁培養系に移動する工程と、を含み、
三次元の細胞クラスタが形成される、方法。
[2] 前記細胞クラスタが、中性プロテアーゼ又はアキュターゼから選択される酵素を使用して、平面接着培養系から前記懸濁培養系に移動される、[1]に記載の方法。
[3] 前記酵素が、中性プロテアーゼである、[2]に記載の方法。
[4] 前記細胞のクラスタが、多能性を維持する、[1]に記載の方法。
[5] 前記多能性幹細胞が、誘導多能性幹細胞、ヒト臍帯組織由来細胞、単為生殖生物、ヒト胚性幹細胞(hES)、及び羊水由来細胞からなる群から選択される、[1]に記載の方法。
[6] 前記細胞が、H1 hESである、[5]に記載の方法。
[7] 前記凝集した細胞が、CD9、SSEA4、TRA−1−60、及びTRA−1−81を発現し、CXCR4の発現を欠く、[1に記載の方法。
[8] 前記細胞クラスタが、キレート剤を使用して、平面接着培養系から前記懸濁培養系に移動される、[1]に記載の方法。
[9] 前記キレート剤が、エチレンジアミン四酢酸(EDTA)である、[8]に記載の方法。
[10] 動的に撹拌される懸濁培養系内で多能性幹細胞を増大させ、分化させる方法であって、
a.平面接着培養系で多能性幹細胞を成長させることと、
b.前記多能性幹細胞を凝集した細胞クラスタに増大させることと、
c.酵素又はキレート剤を使用して、前記多能性幹細胞のクラスタを、前記平面接着培養系から動的懸濁培養系に移動することと、
d.動的に撹拌される懸濁培養系内で前記細胞クラスタを維持することであって、前記幹細胞クラスタが、CD9、SSEA4、TRA−1−60、及びTRA−1−81を発現し、CXCR4の発現を欠く、維持することと、
e.動的撹拌される懸濁培養系内で前記多能性細胞クラスタを分化させて、膵臓前駆細胞集団、神経前駆細胞集団、又は心筋細胞前駆細胞集団を生成することと、を含む、方法。
[11] 前記多能性幹細胞が、誘導多能性幹細胞、ヒト臍帯組織由来細胞、単為生殖生物、ヒト胚性幹細胞(hES)、及び羊水由来細胞からなる群から選択される、[10]に記載の方法。
[12] 前記方法が、β細胞転写因子を発現する膵臓前駆細胞を生成する、[10]に記載の方法。
[13] 前記転写因子が、PDX1及び/又はNKX6.1である、[10]に記載の方法。
[14] [10]に記載の方法によって産生される、前記分化した膵臓前駆細胞の集団を含む、移植可能な幹細胞由来の細胞産物。
[15] 凝集した多能性幹細胞クラスタの分化のためのバイオリアクター培養系であって、
懸濁培地内で維持される多能性幹細胞クラスタであって、前記幹細胞クラスタが、CD9、SSEA4、TRA−1−60、及びTRA−1−81を発現し、CXCR4の発現を欠く、多能性幹細胞クラスタと、
ガラス攪拌懸濁バイオリアクターと、
分化培地と、
温度、pH、及び酸素を調節するための制御と、を含む、バイオリアクター培養系。
[16] 前記懸濁培地が、mTeSR培地である、[15]に記載のバイオリアクター培養系。
[17] 動的に撹拌される懸濁培養系内で多能性幹細胞を増大させ、分化させる方法であって、
a.平面接着培養系で多能性幹細胞を成長させる工程と、
b.酵素を使用して、前記多能性幹細胞を前記平面接着培養系から除去する工程と、
c.前記多能性幹細胞を静的培養物内のマイクロキャリアに接着させる工程と、
d.前記マイクロキャリアに接着される前記多能性細胞を、動的に撹拌される懸濁培養系内で増大させる工程と、
e.動的に撹拌される懸濁培養系内の前記多能性細胞を、膵臓前駆細胞集団に分化させる工程と、を含む、方法。
[18] 前記動的撹拌される懸濁培養系が、スピナフラスコを含む、[17]に記載の方法。
[19] インスリンを産生する膵臓細胞を産生するための方法であって、前記インスリン産生細胞が、懸濁培養系内で多能性幹細胞から産生され、前記多能性幹細胞が、懸濁培養系内で凝集体として培養される、方法。
[20] 前記懸濁分化環境が、およそ無酸素〜周囲の約30%の酸素範囲、0.1%〜約2%の範囲内の脂質、又はこれらの組み合わせを含む、[19]に記載の方法。
[21] 前記細胞が、約11mM未満のグルコースの存在下で懸濁培養系内にある、[19]に記載の方法。
[22] 前記細胞が、約25mMを超えるグルコースの存在下で懸濁培養系内にある、[19]に記載の方法。
[23] 平面又は接着培養系から多能性細胞の懸濁培養を開始するための非酵素的方法であって、移動される前記細胞の前記多能性が維持され、前記平面培養物をキレート剤で処理することを含む、方法。
[24] 分化のために十分な条件下で、多能性細胞を凝集した細胞クラスタとして培養することを含む、ブラキュリの誘導を増加させるための方法。
[25] 細胞周期のG0/G1相における細胞の百分率を増加させるための方法であって、前記方法が、小分子を使用して、多能性細胞を凝集した細胞クラスタとして培養して、多能性状態からの分化を誘導することを含む、方法。
[26] 前記小分子が、MCXである、[25]に記載の方法。
[27] 18〜30時間以内の胚体内胚葉を通して、懸濁培養系内で多能性細胞を分化させるための方法であって、前記培養培地が、アクチビンA、WNT3A、又はいかなるTGFβ族も含まず、前記方法が、少なくとも1つの小分子を含む培養培地を含む、方法。
[28] 前記小分子が、MCXである、[27]に記載の方法。
[29] 懸濁培養系内の細胞を胚体内胚葉に分化させる方法であって、前記培養培地が、MCX及びGDF8、又はWNT3A及びアクチビンAを含む、方法。
[30] 無酸素を誘導することによって分化させるために、閉鎖系懸濁培養系内の多能性細胞の分化を指向する方法。
[31] 懸濁培養系内の細胞の、膵臓運命への分化を指向する方法であって、前記培養培地が、ノギンを含まない、方法。
[32] 前記培養培地が、プロテインキナーゼC作動薬、TPPB、又はこれらの組み合わせを含有する、[31]に記載の方法。
ディスパーゼ/中性プロテアーゼでの、細胞株H1のヒト胚性幹細胞の懸濁及びクラスタリング
継代培養41でのヒト胚性幹細胞株H1の細胞(WA01 cells、WiCell(Madison WI))を、PBS(Catalog# 14190,Invitrogen)で1度洗浄し、DMEM/F12(Invitrogen Catalog# 11330(Grand Island,NY))内で、Dispase(商標)(中性プロテアーゼ、Sigma Aldrich Co LLC, Catalog# D4818(St.Louis,MO))の1mg/mLの溶液で処理した。群体の縁部が丸まって持ち上がり始めるが、培養系表面からの群体の完全な離解の前まで細胞を、37℃で15〜25分間インキュベートした。その後、ディスパーゼを除去し、10μMのY−27632(Axxora Catalog#ALX−270−333(San Diego,CA))を含有するmTeSR(登録商標)1(Stem Cell Technologies(Vancouver,BC,Canada))培地で、培養皿を2度洗浄した。その後、10μMのY−27632を含有するmTeSR(登録商標)1培地を、5mL/60cm2で培養皿に添加し、スクラッパー又はゴム製ポリスマンで表面から細胞を引き上げた。その後、ガラスピペットを使用して、培地及び細胞を50mLの円錐チューブに移動し、クラスタを0.9N(90g(rcf)で3分間遠心分離した。
EDTAでの、細胞株H1のヒト胚性幹細胞の懸濁及びクラスタリング
継代培養41でのヒト胚性幹細胞株H1の細胞(WA01 cells、WiCell(Madison WI))を、PBS(Catalog# 14190,Invitrogen)で1度洗浄し、非酵素的細胞引き上げ/継代培養剤であるEDTA(Lonza,Catalog# 12604−013(St.Louis,MO))で処理した。細胞を、室温で8分間インキュベートした。その後、EDTAを除去し、1〜2分以上(9〜10分間の全EDTA露出)の後、10μMのY−27632(Axxora Catalog#ALX−270−333(San Diego,CA))を含有するmTeSR(登録商標)1培地で平板を濯ぎ、ガラスピペットを使用して、除去された細胞を50mLの円錐チューブ内に回収した。10μMのY−27632を含有するmTeSR(登録商標)1培地で平板の濯ぎを更にもう1度実行し、除去された細胞と共に貯留した。室温での9〜10分間のEDTAへの露出の後、いくつかの細胞は平板上に留まり、引き上げられた細胞は、単一の細胞懸濁液に完全には脱凝集されなかったことに留意すること。代わりに、表面から小さな凝集体として細胞を除去した。その後、ガラスピペットを使用して、培地及び細胞を50mLの円錐チューブに移動し、細胞計数を実行した(NucleoCounter−Chemetec,Cat#YC−T100(Denmark))。必要に応じて、10μMのY−27632を含有する追加のmTeSR(登録商標)1培地を添加して、100〜150万個の細胞/mLの細胞の濃度を作製した。
細胞株H1のヒト胚性幹細胞の、懸濁クラスタリング及び連続的懸濁継代培養
Matrigel(登録商標)でコーティングした組織培養処理したポリスチレン上で成長させた、継代培養40での、ヒト胚性幹細胞株H1の細胞(WA01 cells、WiCell(Madison WI))を、PBS(Catalog# 14190,Invitrogen)で2度洗浄し、Accutase(商標)(1部のPBS対1部のAccutase,Sigma,Catalog# 12604−013(St.Louis,MO))の半強度の溶液で処理した。細胞を、室温で3分半インキュベートした。(Accutase(商標)は、コラーゲン分解性及びタンパク質分解性酵素(甲殻類から単離される)からなる細胞離解溶液であり、哺乳類又は細菌由来の産物を含有しない)。その後、Accutase(商標)を除去し、更に3分後(6分半の全アキュターゼ露出)、10μMのY−27632を含有するmTeSR(登録商標)1培地で平板を濯ぎ、ガラスピペットを使用して、除去された細胞を50mLの円錐チューブ内に回収した。10μMのY−27632を含有するmTeSR(登録商標)1培地で平板の濯ぎを更にもう1度実行し、除去された細胞と共に貯留した。いくつかの細胞は、Accutase(商標)への露出後に平板上に留まり、引き上げられた細胞は、単一の細胞懸濁液に完全には脱凝集されなかった。むしろ、表面から小さな凝集体として細胞を除去した(図3a)。その後、ガラスピペットを使用して、培地及び細胞を50mLの円錐チューブに移動し、細胞計数を実行した。必要に応じて、10μMのY−27632を含有する追加のmTeSR(登録商標)1培地を添加して、100〜150万個の細胞/mLの細胞の濃度を作製した。
懸濁培養したヒト胚性の指向された分化
細胞株H1の幹細胞
継代培養40での、ヒト胚性幹細胞株H1の細胞(WA01 cells、WiCell(Madison WI))を、Accutase(商標)を使用して平面接着培養系から引き上げ、懸濁培養系形式に移動した。実施例3に記載される方法を使用する30回の継代培養のために、動的撹拌される懸濁培養系において細胞を維持した。
b NF=薬局方
c FCC=食品化学物質規格集
d NA=該当なし
e ACS=米国化学会
細胞株H1の接着性培養したヒト胚性幹細胞の、懸濁形式での指向された分化
継代培養41での、ヒト胚性幹細胞株H1の細胞(WA01 cells、WiCell(Madison WI))を、EDTAを使用して平面接着培養系から引き上げ、実施例2に記載される方法を使用して懸濁培養系形式に移動した。
細胞株H1のマイクロキャリア接着性培養したヒト胚性幹細胞の、懸濁形式での指向された分化
Cytodex(登録商標)3マイクロキャリアビーズ(C3)(Sigma−Aldrich,Catalog # C3275)を、15mLのDulbeccoのPBS(DPBS)を含有する、20mLの体積のシリコンコーティングされたガラスシンチレーションバイアル内に、400mgのビーズを4〜24時間浸漬することによって、培養のために調製した。(Cytodex(登録商標)3は、架橋されたデキストランのマトリックスに化学的に連結した変性コラーゲンの薄層からなる。)Cytodex(登録商標)3上の変性コラーゲン層は、トリプシン及びコラゲナーゼを含む、様々なプロテアーゼにより消化されやすく、最大限の細胞の生存性、機能、及び完全性を維持しながら、細胞をマイクロキャリアから除去するための性能を提供する。
H1(WA01)hES細胞株のサブクローン、WB0106を本実施例のために使用した。WB0106を、WiCell Research Institute(Madison,WI)で、DDL−13と称するH1株種材料から誘導した。H1株のWB0106サブクローンを、Matrigel(商標)基質上のmTESR1(商標)培地内に継代培養23で解凍した、DDL−13バイアルから誘導し、その後EDTAを使用して継代培養した。WB0106を継代培養28で凍結し、正常な核型(FISH及びGバンド)、膵臓前駆細胞に分化する能力、並びにクラスタを形成し、懸濁培養系内で増大するコンピテンシーに基づいて、これらの研究のために選択した。
・ヒト胚性幹(hES)細胞株H1、(WA01 cells、WiCell(Madison WI))
・PBS(Catalog# 14190,Invitrogen)
・Y−27632(Axxora Catalog#ALX−270−333(San Diego,CA))
・EDTA(Lonza,Catalog# 12604−013(St.Louis,MO))
・NucleoCounter−(Chemetec,Cat#YC−T100(Denmark))
・Non−Tissue Culture Treated 6ウェルの皿(Becton Dickinson,Catalog# Falcon 351146(Franklin Lakes,NJ))
・Accutase、(Sigma,Catalog# 12604−013(St.Louis,MO))
・pH、及び溶存酸素(DO)バイオリアクタープローブ(Fermprobe pH electrode 225mm,Model# F−635、及びDO Oxyprobe 12mm Sensor,Model # D−145 from Broadley James(Irvine CA))
・免疫保護マクロ封入デバイス(TheraCyte(商標)(Irvine CA))
・Mm HUMAN C−PEPTIDE ELISA(MERCODIA CAT#10−1141−01)
・Glutamax(商標),MCDB131、及びITS−X Invitrogen
・FAF−BSA(Proliant)
・レチノイン酸、グルコース45%(2.5M)、SANT(Shh阻害剤)(Sigma)
・GDF8(Peprotech)
・MCX(JNJ)
・FGF7(R & D Systems)
・LDN−193189(BMP受容体アンタゴニスト)(Stemgent)
・TPPB(プロテインキナーゼC活性薬)(ChemPartner)
・MCDB 131 Cust
凍結維持されたバイオリアクター生成膵臓前駆体クラスタの成熟及び機能
各バイオリアクター研究のために十分な細胞を生成するために、H1 hES(WB0106)細胞の1つの継代培養31マスター細胞バンクバイアルを解凍した。5つのMatrigel(商標)コーティングされた2−Layer CellSTACK(商標)(CS2)を播種するために十分な細胞が生成されるまで、EDTA継代培養を使用して、Matrigel(商標)上でのいくつかの継代培養のために、mTeSR1(商標)培地内で、接着性条件下で細胞を増大させた。CS2内で成長する接着性細胞が70%コンフルエントになると、C−flex(商標)チュービングアセンブリキャップを、隣接するポンプチュービングと共に、培地ポートに結合して、系を閉鎖した。系が閉鎖した後、Terumo溶接機を介してC−flex(商標)で袋又はボトルを溶接し、蠕動ポンプを使用して全液体体積(培地、PBS-/-、Accutase(商標)、又は懸濁される細胞)を移動した。
・上記の表10における基本培地は、ステージ1〜5でGlutamaxが補助において使用されない際、任意で5mMのグルコースを含み得る。
・任意で、上記に示す表におけるステージ4でCypi([100nM])が添加され得る。
3リットルのDASGIPバイオリアクター内で、70rpmの撹拌速度で混合される、2.7リットルのDASGIP攪拌懸濁バイオリアクター内で細胞凝集体が受ける剪断応力を決定した。剪断応力値を計算するために、以下に述べる想定がなされた。
1.細胞凝集体上に課される最大剪断応力は、乱流渦の結果ではない
2.細胞凝集体上に課される最大剪断応力は、凝集体間、又は凝集体−羽根車間の衝突の結果ではない
3.バッフル(すなわち、ディップチューブ、及びプローブ)により課される剪断応力は、これらの計算においては言及されていない
レイノルズ数:
細胞株WA01から胚体内胚葉へのヒト胚性幹細胞の分化:懸濁培養系内でのMCX/GDF8の役割
三角/振とう器フラスコ内、スピナフラスコ内、あるいは2%の脂肪酸を含まないBSA(Catalog # 68700,Proliant(IA))、1×Glutamax(商標)(Catalog # 35050−079,Invitrogen(CA))、追加の2.5mMのグルコース(Catalog # G8769,Sigma)、及び1:50,000の貯蔵濃度のITS−X(Catalog # 51500056,Invitrogen(CA))で補助した、3.64g/mLの重炭酸ナトリウム及び5.5mMのグルコース(Catalog # A13051DJ,Invitrogen(CA))を含有するMCDB−131培地内の、コーティングされない超低結合、又は非組織培養処理した6ウェルの平板内で、多能性ヒト胚性幹細胞株H1(NIHコード:WA01)からのクラスタを、0.25×106〜2×106個の細胞/mLの範囲の細胞密度で播種した。本出願の目的のために、この様式で補助したMCDB−131培地を、「ステージ1基本培地」と称することとする。この培地内のクラスタを、分化の第1日目に3μMのMCX(GSK3B阻害剤、14−プロパ−2−エン−1−イル−3,5,7,14,17,23,27−ヘプタアザテトラシクロ[19.3.1.1〜2,6〜.1〜8,12〜]ヘプタコサ−1(25),2(27),3,5,8(26),9,11,21,23−ノナエン−16−オン、米国特許出願第12/494,789号;その全体が本明細書に参照によって組み込まれる)及び100ng/mLのGDF−8(Catalog # 120−00,Peprotech)、又は3μMのMCXのみ、又は20ng/mLのWNT−3A(Catalog # 1324−WN−002,R&D Systems(MN))+100ng/mLのアクチビンA(Catalog # 338−AC,R&D Systems(MN))、又は20ng/mLのWNT−3Aのみで処理した。2日目に、100ng/mLのGDF8又は100ng/mLのアクチビンAのいずれかで補助したステージ1基本培地に細胞を移動した。フローサイトメトリー、PCR、及びウエスタンプロット分析のために、ゼロ(基本培地+補助の添加の直前)から分化開始の72時間後までの範囲の様々な時点で試料を回収した。
細胞株WA01から胚体内胚葉へのヒト胚性幹細胞の分化:懸濁培養系内でのMCX化合物濃縮物の用量反応
三角/振とう器フラスコ、又はスピナフラスコ内で、実施例9に記載のステージ1基本培地内で、多能性ヒト胚性幹細胞株H1(NIHコード:WA01)からのクラスタを、0.25×106〜2×106個の細胞/mLの範囲の細胞密度で播種した。クラスタを、分化の1日目に、1.5、2、3、又は4μMのMCXを含有するステージ1基本培地で、及び2日目に、100ng/mLのGDF−8を含有する新鮮なステージ1基本培地で処理した。3日目には培地交換を実行しなかった。分化の3日目の終了時点で、フローサイトメトリー及びPCR分析のために試料を回収した。
細胞株WA01から胚体内胚葉へのヒト胚性幹細胞の分化:懸濁培養系内の培地交換頻度の役割
三角/振とう器フラスコ、又はスピナフラスコ内で、実施例9に記載のステージ1基本培地内で、多能性ヒト胚性幹細胞株H1(NIHコード:WA01)からのクラスタを、0.25×10^6〜2×10^6個の細胞/mLの範囲の細胞密度で播種した。クラスタを、分化の1日目に、3μMのMCXを含有するステージ1基本培地で、及び2日目に、100ng/mLのGDF−8を含有する新鮮なステージ1基本培地で処理した。対照培養系は、3日目に培地交換を受けた;別個の管に対して、3日目には培地交換を実行しなかった。分化の3日目の終了時点で、フローサイトメトリー及びPCR分析のために試料を回収した。
細胞株WA01から胚体内胚葉へのヒト胚性幹細胞の分化:懸濁培養系内でのGlutamax(商標)の使用
三角/振とう器フラスコ、又はスピナフラスコ内で、多能性ヒト胚性幹細胞株H1(NIHコード:WA01)からのクラスタを、0.25×106〜2×106個の細胞/mLの範囲の細胞密度で播種した。
細胞株WA01から胚体内胚葉へのヒト胚性幹細胞の分化:懸濁培養系内での重炭酸ナトリウム濃縮物の役割
三角/振とう器フラスコ、又はスピナフラスコ内で、実施例9に記載するステージ1基本培地(3.64g/lの重炭酸ナトリウムを含有)内、又は2.43g/lの重炭酸ナトリウムを含有する修飾ステージ1基本培地内のいずれかで、多能性ヒト胚性幹細胞株H1(NIHコード:WA01)からのクラスタを、0.25×106〜2×106個の細胞/mLの範囲の細胞密度で播種した。実施例12に記載するように、MCX及びGDF−8を含有するステージ1基本培地で、クラスタを処理した。分化の3日目の終了時点で、フローサイトメトリーのために試料を回収した。分化の各日における、位相差画像もまた撮像した。
測定可能なバイオリアクタープロセスにおける、ヒト誘導多能性幹細胞からの膵臓前駆体クラスタの生成
細胞治療は、一用量につき、大量(>108)の細胞を必要とする。この実施例は、現在の細胞治療製造の慣行で可能であるものよりも、3〜5桁大きい誘導多能性幹細胞(iPS細胞)集団を分化させることができるプロセスを実証する。
・ヒト胚性幹(hES)細胞株H1、(WA01cells、WiCell(Madison WI))
・PBS(Catalog# 14190,Invitrogen)
・Y−27632(Axxora Catalog#ALX−270−333(San Diego,CA))
・EDTA(Lonza,Catalog# 12604−013(St.Louis,MO))
・NucleoCounter−(Chemetec,Cat#YC−T100(Denmark))
・Non−Tissue Culture Treated 6ウェルの皿(Becton Dickinson,Catalog#Falcon 351146(Franklin Lakes,NJ))
・Accutase(Sigma,Catalog# 12604−013(St.Louis,MO))
・pH、及び溶存酸素(DO)バイオリアクタープローブ(Fermprobe pH electrode 225mm,Model # F−635、及びDO Oxyprobe 12mm Sensor,Model # D−145 from Broadley James(Irvine CA))
・免疫保護マクロ封入デバイス(TheraCyte(商標)(Irvine CA))
・ヒトC−ペプチドELISA(MERCODIA CAT# 10−1141−01)
・Glutamax(商標),MCDB131、及びITS−X Invitrogen
FAF−BSA(Proliant)
・レチノイン酸、グルコース45%(2.5M)、SANT(Shh阻害剤)(Sigma)
・GDF8(Peprotech)
・MCX(JNJ)
・FGF7(R & D Systems)
・LDN−193189(BMP受容体アンタゴニスト)(Stemgent)
・TPPB(プロテインキナーゼC活性薬)(ChemPartner)
細胞株WA01から胚体内胚葉へのヒト胚性幹細胞の分化:懸濁培養系内でのMCX/GDF8の細胞周期調節剤としての役割
三角振とう器フラスコ内の、2%の脂肪酸を含まないBSA(Catalog # 68700,Proliant(IA))、1×Glutamax(商標)(Catalog # 35050−079,Invitrogen(CA))、追加の2.5mMのグルコース(Catalog # G8769,Sigma)、及び1:50,000の貯蔵濃度のITS−X(Catalog # 51500056,Invitrogen(CA))で補助した、3.64g/mLの重炭酸ナトリウム、及び5.5mMのグルコース(Catalog # 13051DJ,Invitrogen(CA))を含有するMCDB−131培地内で、多能性ヒト胚性幹細胞株H1(NIHコード:WA01)からのクラスタを、0.5×106個の細胞/mLで播種した。本実施例の目的のために、この様式で補助したMCDB−131培地を、ステージ1基本培地又は「無溶媒」培地と称することとする。GSK3B阻害剤、14−プロパ−2−エン−1−イル−3,5,7,14,17,23,27−ヘプタアザテトラシクロ[19.3.1.1〜2,6〜.1〜8,12〜]ヘプタコサ−1(25),2(27),3,5,8(26),9,11,21,23−ノナエン−16−オン(米国特許出願第12/494,789号;その全体が本明細書に参照によって組み込まれる)を、「MCX」と称する。
測定可能な懸濁分化プロセスを使用する、外胚葉組織及び中胚葉組織の生成
本実施例は、多能性幹細胞(PSC)の増大及び分化の両方をして、外胚葉組織又は中胚葉組織の生成のための測定可能な製造プロセスを達成することができるプロセスを実証する。
材料:
ヒト臍帯組織由来細胞(米国特許第7,510,873号に開示)
誘導可能多能性幹細胞
単為生殖生物
ヒト胚性幹(hES)細胞株H1、(WA01 cells,WiCell(Madison WI))
PBS(Catalog# 14190,Invitrogen)
Y−27632(Axxora Catalog#ALX−270−333(San Diego,CA))
EDTA、(Lonza,Catalog# 12604−013(St.Louis,MO))
NucleoCounter−(Chemetec,Cat#YC−T100(Denmark))
非組織培養処理した6ウェルの皿(Becton Dickinson,Catalog# Falcon 351146(Franklin Lakes,NJ))
アキュターゼ、(Sigma,Catalog# 12604−013(St.Louis,MO))
pH、及び溶存酸素(DO)バイオリアクタープローブ(Fermprobe pH electrode 225mm,Model # F−635、及びDO Oxyprobe 12mm Sensor,Model # D−145 from Broadley James(Irvine CA))
免疫保護マクロ封入デバイス(TheraCyte(商標)(Irvine CA))
ヒトC−ペプチドELISA(MERCODIA CAT# 10−1141−01)
Glutamax(商標)、MCDB131、及びITS−X Invitrogen
FAF−BSA(Proliant)
レチノイン酸、グルコース45%(2.5M)、SANT(Shh阻害剤)(Sigma)
GDF8(Peprotech)
MCX(JNJ)
IWP−4(WNT3阻害剤)Stemgent
MCDB131培地
MCDB131培地(カスタム化)−NaCO3レベルを3.64g/Lに上昇させるために修飾
Claims (13)
- ブラキュリ遺伝子の発現を増加させる方法であって、
平板接着培養において多能性幹細胞を凝集した細胞クラスターに増大させる工程、
酵素又はキレート剤を使用して、前記凝集した細胞クラスターを単一の細胞に脱凝集させずに、前記凝集した細胞クラスターを取り出す工程、
前記凝集した細胞クラスターを再懸濁し、低結合平板において一晩インキュベートする工程、および
環式アニリンピリジノトリアジンで補充された培地中の動的懸濁培養において前記多能性幹細胞を凝集した細胞クラスターとして培養する工程
を含む、方法。 - 多能性細胞を分化させるための方法であって、
平板接着培養において多能性幹細胞を凝集した細胞クラスターに増大させる工程、
酵素又はキレート剤を使用して、前記凝集した細胞クラスターを単一の細胞に脱凝集させずに、前記凝集した細胞クラスターを取り出す工程、
前記細胞クラスターを再懸濁し、低結合平板において一晩インキュベートする工程、および
前記多能性細胞を、凝集した細胞クラスターとして、動的懸濁培養において18〜30時間の期間内に胚体内胚葉細胞へと分化させる工程であって、前記培地が、アクチビンA、WNT3A、又はいかなるTGFβ族も含まず、環式アニリンピリジノトリアジンで補充されたものである工程
を含む、方法。 - 前記培地がさらにGDF8で補充されている、請求項1または2に記載の方法。
- 前記環式アニリンピリジノトリアジンが14−プロパ−2−エン−1−イル−3,5,7,14,17,23,27−ヘプタアザテトラシクロ[19.3.1.1〜2,6−〜.1〜8,12.〜]ヘプタコサ−1(25),2(27),3,5,8(26),9,11,21,23−ノン−アエン−16−オンである、請求項1または2に記載の方法。
- 前記環式アニリンピリジノトリアジンが14−メチル−3,5,7,14,18,24,28−ヘプタアザテトラシクロ[20.3.1.1〜2,6〜.−1〜8,12〜]オクタコサ−1(26),2(28),3,5,8(27),9,11,22,24−ノナエン−17−オン、
又は5−クロロ−1,8,10,12,16,22,26,32−オクタアザペンタシクロ[24.2.2.1〜3,7〜−1〜9,13〜.1〜14,18〜]トリトリアコンタ−3(33),4,6,9(32),10−,12,14(31),15,17−ノナエン−23−オンである、請求項1または2に記載の方法。 - 前記環式アニリンピリジノトリアジンを1μM〜5μM含む、請求項4または5に記載の方法。
- 多能性幹細胞の凝集クラスターを胚体内胚葉に分化させる方法であって、
平板接着培養において多能性幹細胞を凝集した細胞クラスターに増大させる工程、
酵素又はキレート剤を使用して、前記凝集した細胞クラスターを単一の細胞に脱凝集させずに、前記凝集した細胞クラスターを取り出す工程、
前記凝集した細胞クラスターを再懸濁し、低結合平板において一晩インキュベートする工程、および
前記多能性幹細胞を、環式アニリンピリジノトリアジン及びGDF8で補充された培地中で動的懸濁培養において培養する工程であって、前記環式アニリンピリジノトリアジンが14−プロパ−2−エン−1−イル−3,5,7,14,17,23,27−ヘプタアザテトラシクロ[19.3.1.1〜2,6−〜.1〜8,12.〜]ヘプタコサ−1(25),2(27),3,5,8(26),9,11,21,23−ノン−アエン−16−オンである工程
を含む、方法。 - ブラキュリ遺伝子の促進を増加させる、請求項7に記載の方法。
- 細胞周期のG0/G1相における細胞の百分率を増加させる、請求項7に記載の方法。
- 懸濁培養がマイクロキャリアを含む、請求項1、2及び7のいずれか一項に記載の方法。
- 前記多能性幹細胞がヒト胚性幹細胞である、請求項1、2及び7のいずれか一項に記載の方法。
- 前記培養培地が1mM〜8mMのグルコースで補充されている、請求項1、2及び7のいずれか一項に記載の方法。
- 前記培養培地がITS−Xで補充されている、請求項1、2及び7のいずれか一項に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261747799P | 2012-12-31 | 2012-12-31 | |
US61/747,799 | 2012-12-31 | ||
US201361962158P | 2013-11-01 | 2013-11-01 | |
US61/962,158 | 2013-11-01 | ||
PCT/US2013/078191 WO2014106141A1 (en) | 2012-12-31 | 2013-12-30 | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016504037A JP2016504037A (ja) | 2016-02-12 |
JP2016504037A5 JP2016504037A5 (ja) | 2018-06-14 |
JP6529440B2 true JP6529440B2 (ja) | 2019-06-12 |
Family
ID=51022103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015550826A Active JP6529440B2 (ja) | 2012-12-31 | 2013-12-30 | 膵内分泌細胞への分化のためのヒト多能性細胞の懸濁及びクラスタリング |
Country Status (16)
Country | Link |
---|---|
US (1) | US10377989B2 (ja) |
EP (2) | EP4039798A1 (ja) |
JP (1) | JP6529440B2 (ja) |
KR (1) | KR20150103203A (ja) |
CN (1) | CN105705634A (ja) |
AU (1) | AU2013370228B2 (ja) |
BR (1) | BR112015015714A2 (ja) |
CA (1) | CA2896750A1 (ja) |
DK (1) | DK2938722T3 (ja) |
ES (1) | ES2906998T3 (ja) |
HK (1) | HK1217727A1 (ja) |
MX (1) | MX2015008619A (ja) |
PH (1) | PH12015501477A1 (ja) |
RU (2) | RU2687379C2 (ja) |
SG (2) | SG10201709384SA (ja) |
WO (1) | WO2014106141A1 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240014630A (ko) | 2013-06-11 | 2024-02-01 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | SC-β 세포 및 조성물 그리고 그 생성 방법 |
MX2016005657A (es) * | 2013-11-01 | 2017-01-05 | Janssen Biotech Inc | Suspensión y agrupamiento de células madre humanas pluripotentes para la diferenciación a células endocrinas pancreáticas. |
CN106536718B (zh) * | 2014-05-21 | 2021-04-27 | 国立大学法人京都大学 | 胰芽细胞的制造方法及含有胰芽细胞的胰疾病治疗剂 |
EP4374863A2 (en) | 2014-12-18 | 2024-05-29 | President and Fellows of Harvard College | Methods for generating stem cell-derived beta cells and uses thereof |
WO2016100930A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | Methods for generating stem cell-derived b cells and methods of use thereof |
US10443042B2 (en) | 2014-12-18 | 2019-10-15 | President And Fellows Of Harvard College | Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof |
US9944894B2 (en) | 2015-01-16 | 2018-04-17 | General Electric Company | Pluripotent stem cell expansion and passage using a rocking platform bioreactor |
JP2016202172A (ja) * | 2015-04-16 | 2016-12-08 | 国立大学法人京都大学 | 疑似膵島の製造方法 |
WO2017127921A1 (en) * | 2016-01-26 | 2017-08-03 | Centre For Commercialization Of Regenerative Medicine | Method for dissociating cell aggregates |
MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
MA45502A (fr) | 2016-06-21 | 2019-04-24 | Janssen Biotech Inc | Génération de cellules bêta fonctionnelles dérivées de cellules souches pluripotentes humaines ayant une respiration mitochondriale glucose-dépendante et une réponse en sécrétion d'insuline en deux phases |
US10391156B2 (en) | 2017-07-12 | 2019-08-27 | Viacyte, Inc. | University donor cells and related methods |
WO2019018818A1 (en) * | 2017-07-21 | 2019-01-24 | Semma Therapeutics, Inc. | REAGGREGATION OF BETA PANCREATIC CELLS DERIVED FROM STEM CELLS |
MX2020002421A (es) * | 2017-09-11 | 2020-07-13 | Novo Nordisk As | Enriquecimiento de celulas que coexpresan nkx6.1 y peptido c derivadas in vitro a partir de celulas madre. |
MX2020004939A (es) * | 2017-11-15 | 2020-11-11 | Semma Therapeutics Inc | Fabricacion de composiciones de celulas islote y metodos de uso de las mismas. |
US20200399602A1 (en) * | 2018-01-18 | 2020-12-24 | Agency For Science, Technology And Research | Method for Differentiation of Human Pluripotent Stem Cell Lines in Suspension Culture |
EP3833365A4 (en) | 2018-08-10 | 2022-05-11 | Vertex Pharmaceuticals Incorporated | ISLE DIFFERENTIATION DERIVED FROM STEM CELLS |
US10724052B2 (en) | 2018-09-07 | 2020-07-28 | Crispr Therapeutics Ag | Universal donor cells |
AU2020283056B2 (en) | 2019-05-31 | 2023-06-08 | Viacyte, Inc. | A biocompatible membrane composite |
AU2020283150B2 (en) | 2019-05-31 | 2023-08-17 | Viacyte, Inc. | Cell encapsulation devices with controlled oxygen diffusion distances |
US20220234006A1 (en) | 2019-05-31 | 2022-07-28 | W. L. Gore & Associates, Inc. | A biocompatible membrane composite |
CA3139585C (en) | 2019-05-31 | 2024-01-23 | W. L. Gore & Associates, Inc. | A biocompatible membrane composite |
EP4025690A1 (en) | 2019-09-05 | 2022-07-13 | CRISPR Therapeutics AG | Universal donor cells |
MX2022002663A (es) | 2019-09-05 | 2022-04-07 | Crispr Therapeutics Ag | Celulas donantes universales. |
AU2020399213A1 (en) * | 2019-12-11 | 2022-05-05 | Repairon Gmbh | Expansion of stem cells in suspension in a bioreactor |
JP2024503290A (ja) | 2020-12-31 | 2024-01-25 | クリスパー セラピューティクス アクチェンゲゼルシャフト | ユニバーサルドナー細胞 |
WO2022203051A1 (ja) * | 2021-03-25 | 2022-09-29 | 株式会社カネカ | 多能性幹細胞集団の製造方法 |
CA3222122A1 (en) * | 2021-06-15 | 2022-12-22 | Lara SILVERMAN | Novel methods for production of therapeutic mammalian cells and cell spheres and compositions of same |
WO2023229819A1 (en) * | 2022-05-24 | 2023-11-30 | Bluerock Therapeutics Lp | Methods of making oligodendrocyte progenitor cells |
Family Cites Families (273)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3209652A (en) | 1961-03-30 | 1965-10-05 | Burgsmueller Karl | Thread whirling method |
AT326803B (de) | 1968-08-26 | 1975-12-29 | Binder Fa G | Maschenware sowie verfahren zur herstellung derselben |
US3935067A (en) | 1974-11-22 | 1976-01-27 | Wyo-Ben Products, Inc. | Inorganic support for culture media |
CA1201400A (en) | 1982-04-16 | 1986-03-04 | Joel L. Williams | Chemically specific surfaces for influencing cell activity during culture |
US4499802A (en) | 1982-09-29 | 1985-02-19 | Container Graphics Corporation | Rotary cutting die with scrap ejection |
US4537773A (en) | 1983-12-05 | 1985-08-27 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid derivatives |
US4557264A (en) | 1984-04-09 | 1985-12-10 | Ethicon Inc. | Surgical filament from polypropylene blended with polyethylene |
US5215893A (en) | 1985-10-03 | 1993-06-01 | Genentech, Inc. | Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
US5089396A (en) | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
US4737578A (en) | 1986-02-10 | 1988-04-12 | The Salk Institute For Biological Studies | Human inhibin |
US5863531A (en) | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
US5759830A (en) | 1986-11-20 | 1998-06-02 | Massachusetts Institute Of Technology | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5567612A (en) | 1986-11-20 | 1996-10-22 | Massachusetts Institute Of Technology | Genitourinary cell-matrix structure for implantation into a human and a method of making |
NZ229354A (en) | 1988-07-01 | 1990-09-26 | Becton Dickinson Co | Treating polymer surfaces with a gas plasma and then applying a layer of endothelial cells to the surface |
EP0363125A3 (en) | 1988-10-03 | 1990-08-16 | Hana Biologics Inc. | Proliferated pancreatic endocrine cell product and process |
SU1767433A1 (ru) | 1989-11-27 | 1992-10-07 | Пермский государственный медицинский институт | Способ определени инсулинорезистентности имунного генеза у больных сахарным диабетом I типа |
US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
ES2134212T3 (es) | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano. |
US5449383A (en) | 1992-03-18 | 1995-09-12 | Chatelier; Ronald C. | Cell growth substrates |
GB9206861D0 (en) | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
CA2114282A1 (en) | 1993-01-28 | 1994-07-29 | Lothar Schilder | Multi-layered implant |
JP3525221B2 (ja) | 1993-02-17 | 2004-05-10 | 味の素株式会社 | 免疫抑制剤 |
AU687386B2 (en) | 1993-04-08 | 1998-02-26 | Human Cell Cultures, Inc. | Cell culturing method and medium |
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
GB9310557D0 (en) | 1993-05-21 | 1993-07-07 | Smithkline Beecham Plc | Novel process and apparatus |
TW257671B (ja) | 1993-11-19 | 1995-09-21 | Ciba Geigy | |
US6001647A (en) | 1994-04-28 | 1999-12-14 | Ixion Biotechnology, Inc. | In vitro growth of functional islets of Langerhans and in vivo uses thereof |
US5834308A (en) | 1994-04-28 | 1998-11-10 | University Of Florida Research Foundation, Inc. | In vitro growth of functional islets of Langerhans |
US6703017B1 (en) | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
JP4079461B2 (ja) | 1994-12-29 | 2008-04-23 | 中外製薬株式会社 | Il−6アンタゴニストを含んでなる抗腫瘍剤の作用増強剤 |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5718922A (en) | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
US5908782A (en) | 1995-06-05 | 1999-06-01 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
US5681561A (en) | 1995-06-07 | 1997-10-28 | Life Medical Sciences, Inc. | Compositions and methods for improving autologous fat grafting |
EP0986635A4 (en) | 1997-01-10 | 2001-11-07 | Life Technologies Inc | SERUM SUBSTITUTE FOR EMBRYONIC STEM CELLS |
PT1028954E (pt) | 1997-04-24 | 2003-11-28 | Ortho Mcneil Pharm Inc | Imidazoles substituidos uteis no tratamento de doencas inflamatorias |
CA2294944A1 (en) | 1997-07-03 | 1999-01-14 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells from peripheral blood |
US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
EP1015576B1 (en) | 1997-09-16 | 2005-05-04 | Egea Biosciences, LLC | Method for the complete chemical synthesis and assembly of genes and genomes |
AU1197699A (en) | 1997-10-23 | 1999-05-10 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
AR014195A1 (es) | 1997-12-29 | 2001-02-07 | Ortho Mcneil Pharm Inc | Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos |
WO1999047163A2 (en) | 1998-03-18 | 1999-09-23 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
MY132496A (en) | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
US6413773B1 (en) | 1998-06-01 | 2002-07-02 | The Regents Of The University Of California | Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation |
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US6610540B1 (en) | 1998-11-18 | 2003-08-26 | California Institute Of Technology | Low oxygen culturing of central nervous system progenitor cells |
US6413556B1 (en) | 1999-01-08 | 2002-07-02 | Sky High, Llc | Aqueous anti-apoptotic compositions |
EP1144597A2 (en) | 1999-01-21 | 2001-10-17 | Vitro Diagnostics, Inc. | Immortalized cell lines and methods of making the same |
US6815203B1 (en) | 1999-06-23 | 2004-11-09 | Joslin Diabetes Center, Inc. | Methods of making pancreatic islet cells |
US6306424B1 (en) | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
US6333029B1 (en) | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
AU7719300A (en) | 1999-09-27 | 2001-04-30 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
US6685936B2 (en) | 1999-10-12 | 2004-02-03 | Osiris Therapeutics, Inc. | Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation |
US20030082155A1 (en) | 1999-12-06 | 2003-05-01 | Habener Joel F. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
JP2003517592A (ja) | 1999-12-13 | 2003-05-27 | ザ スクリプス リサーチ インスティチュート | 膵島αおよびβ前駆体の同定ならびに単離のためのマーカー |
US7005252B1 (en) | 2000-03-09 | 2006-02-28 | Wisconsin Alumni Research Foundation | Serum free cultivation of primate embryonic stem cells |
US7439064B2 (en) | 2000-03-09 | 2008-10-21 | Wicell Research Institute, Inc. | Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium |
US6436704B1 (en) | 2000-04-10 | 2002-08-20 | Raven Biotechnologies, Inc. | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
US6458589B1 (en) | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
AU2001274624A1 (en) | 2000-06-26 | 2002-01-08 | Renomedix Institute Inc. | Cell fraction containing cells capable of differentiating into nervous system cells |
IL155367A0 (en) | 2000-10-23 | 2003-12-23 | Smithkline Beecham Corp | NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES |
ES2245994T3 (es) | 2000-12-08 | 2006-02-01 | Ortho-Mcneil Pharmaceutical, Inc. | Compuestos macro-heterociclicos utilizados como inhibidores de quinasa. |
BR0116468A (pt) | 2000-12-08 | 2004-06-29 | Ortho Mcneil Pharm Inc | Compostos de pirrolina substituìda por indazolila como inibidores de cinase |
US6599323B2 (en) | 2000-12-21 | 2003-07-29 | Ethicon, Inc. | Reinforced tissue implants and methods of manufacture and use |
CA2435826A1 (en) | 2001-01-24 | 2002-08-01 | The Government Of The United States Of America | Differentiation of stem cells to pancreatic endocrine cells |
ES2359391T3 (es) | 2001-01-25 | 2011-05-23 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulación de compuestos de acido boronico. |
US6656488B2 (en) | 2001-04-11 | 2003-12-02 | Ethicon Endo-Surgery, Inc. | Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering |
WO2002086107A2 (en) | 2001-04-19 | 2002-10-31 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | A method for differentiating stem cells into insulin-producing cells |
JP4296781B2 (ja) | 2001-04-24 | 2009-07-15 | 味の素株式会社 | 幹細胞及びその分離方法 |
JP2004531262A (ja) | 2001-05-15 | 2004-10-14 | ラッパポート ファミリー インスチチュート フォア リサーチ イン ザ メディカル サイエンシズ | ヒト胚性幹細胞由来インスリン産生細胞 |
US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
KR100418195B1 (ko) | 2001-07-05 | 2004-02-11 | 주식회사 우리기술 | 전력케이블의 다중절연진단장치 및 그 방법 |
GB0117583D0 (en) | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
WO2003014313A2 (en) | 2001-08-06 | 2003-02-20 | Bresagen, Ltd. | Alternative compositions and methods for the culture of stem cells |
US6617152B2 (en) | 2001-09-04 | 2003-09-09 | Corning Inc | Method for creating a cell growth surface on a polymeric substrate |
EP1298201A1 (en) * | 2001-09-27 | 2003-04-02 | Cardion AG | Process for the production of cells exhibiting an islet-beta-cell-like state |
CA2463914A1 (en) | 2001-10-18 | 2003-04-24 | Ixion Biotechnology, Inc. | Conversion of liver stem and progenitor cells to pancreatic functional cells |
AU2002363659B2 (en) | 2001-11-15 | 2008-09-25 | Children's Medical Center Corporation | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof |
US7033831B2 (en) | 2001-12-07 | 2006-04-25 | Geron Corporation | Islet cells from human embryonic stem cells |
JP4653952B2 (ja) | 2001-12-07 | 2011-03-16 | サイトリ セラピューティクス インコーポレイテッド | 処理済み脂肪吸引細胞で患者を治療するためのシステムと方法 |
WO2003054169A1 (en) | 2001-12-21 | 2003-07-03 | Thromb-X Nv | Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability |
AU2002367091A1 (en) | 2001-12-28 | 2003-07-15 | Cellartis Ab | A method for the establishment of a pluripotent human blastocyst-derived stem cell line |
US20030162290A1 (en) | 2002-01-25 | 2003-08-28 | Kazutomo Inoue | Method for inducing differentiation of embryonic stem cells into functioning cells |
US20030180268A1 (en) | 2002-02-05 | 2003-09-25 | Anthony Atala | Tissue engineered construct for supplementing or replacing a damaged organ |
EP1498478A1 (en) | 2002-04-17 | 2005-01-19 | Otsuka Pharmaceutical Co., Ltd. | Method of forming pancreatic beta cells from mesenchymal cells |
US20040161419A1 (en) | 2002-04-19 | 2004-08-19 | Strom Stephen C. | Placental stem cells and uses thereof |
WO2003095452A1 (en) | 2002-05-08 | 2003-11-20 | Janssen Pharmaceutica N.V. | Substituted pyrroline kinase inhibitors |
US20060003446A1 (en) | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
EP1578925A4 (en) | 2002-05-28 | 2006-10-11 | Becton Dickinson Co | METHOD FOR IN VITRO EXPANSION AND TRANSDIFFERENCING HUMAN PANCREATIC AZINUS CELLS FOR INSULIN-PRODUCING CELLS |
BR0311821A (pt) | 2002-06-05 | 2005-04-05 | Janssen Pharmaceutica Nv | Derivados de bisindolil-maleimid como inibidores de cinase |
GB0212976D0 (en) | 2002-06-06 | 2002-07-17 | Tonejet Corp Pty Ltd | Ejection method and apparatus |
CN1171991C (zh) | 2002-07-08 | 2004-10-20 | 徐如祥 | 人神经干细胞的培养方法 |
US6877147B2 (en) | 2002-07-22 | 2005-04-05 | Broadcom Corporation | Technique to assess timing delay by use of layout quality analyzer comparison |
US7838290B2 (en) | 2002-07-25 | 2010-11-23 | The Scripps Research Institute | Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith |
JP2005534345A (ja) | 2002-07-29 | 2005-11-17 | エス セル インターナショナル ピーティーイー リミテッド | インスリン陽性、グルコース応答性細胞の分化のための多段階方法 |
US20040063204A1 (en) | 2002-08-14 | 2004-04-01 | Lijun Yang | Bone marrow cell differentiation |
US7371576B2 (en) | 2002-09-06 | 2008-05-13 | Reneuron, Inc. | CD56 positive human adult pancreatic endocrine progenitor cells |
US9969977B2 (en) | 2002-09-20 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
US20040062753A1 (en) | 2002-09-27 | 2004-04-01 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
AU2003285172A1 (en) | 2002-11-08 | 2004-06-03 | The Johns Hopkins University | Human embryonic stem cell cultures, and compositions and methods for growing same |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
US20060040385A1 (en) | 2002-12-05 | 2006-02-23 | Technion Research & Development Foundation Ltd. | Cultured human pancreatic islets, and uses thereof |
DK1572984T3 (en) | 2002-12-16 | 2016-06-13 | Technion Res & Dev Foundation | FEEDER CELL-FREE, XENOPHRIC CULTIVATION SYSTEM FOR HUMAN EMBRYONAL STEM CELLS |
US20050118148A1 (en) | 2002-12-20 | 2005-06-02 | Roland Stein | Compositions and methods related to mammalian Maf-A |
RU2359671C2 (ru) | 2003-01-29 | 2009-06-27 | Такеда Фармасьютикал Компани Лимитед | Способ получения препарата с покрытием |
US7976853B2 (en) | 2003-01-29 | 2011-07-12 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
WO2004073633A2 (en) | 2003-02-14 | 2004-09-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating the development of stem cells |
WO2005045001A2 (en) | 2003-02-14 | 2005-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Insulin-producing cells derived from stem cells |
WO2004087885A2 (en) | 2003-03-27 | 2004-10-14 | Ixion Biotechnology, Inc. | Method for transdifferentiation of non-pancreatic stem cells to the pancreatic pathway |
US20060194315A1 (en) | 2003-03-31 | 2006-08-31 | Condie Brian G | Compositions and methods for the control, differentiaton and/or manipulation of pluripotent cells through a gamma-secretase signaling pathway |
US20090203141A1 (en) | 2003-05-15 | 2009-08-13 | Shi-Lung Lin | Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant RNA agents |
PL2338982T3 (pl) | 2003-06-27 | 2016-01-29 | Depuy Synthes Products Inc | Komórki poporodowe pochodzące z tkanek pępowinowych i sposoby ich wytwarzania i zastosowania |
IL161903A0 (en) | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
ITRM20030395A1 (it) | 2003-08-12 | 2005-02-13 | Istituto Naz Per Le Malattie Infettive Lazz | Terreno di coltura per il mantenimento, la proliferazione e il differenziamento di cellule di mammifero. |
US7569385B2 (en) | 2003-08-14 | 2009-08-04 | The Regents Of The University Of California | Multipotent amniotic fetal stem cells |
US7157275B2 (en) | 2003-08-15 | 2007-01-02 | Becton, Dickinson And Company | Peptides for enhanced cell attachment and growth |
US20060205072A1 (en) | 2003-08-27 | 2006-09-14 | Nobuko Uchida | Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
WO2005058301A1 (en) | 2003-12-17 | 2005-06-30 | Allergan, Inc. | Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
US20060030042A1 (en) | 2003-12-19 | 2006-02-09 | Ali Brivanlou | Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime |
US7625753B2 (en) | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
CN1946838A (zh) | 2003-12-23 | 2007-04-11 | 赛瑟拉公司 | 定形内胚层 |
US7541185B2 (en) | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
US20050266554A1 (en) | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
DK1709159T3 (da) | 2003-12-23 | 2019-07-29 | Viacyte Inc | Definitiv endoderm |
TWI334443B (en) | 2003-12-31 | 2010-12-11 | Ind Tech Res Inst | Method of single cell culture of undifferentiated human embryonic stem cells |
US20050233446A1 (en) | 2003-12-31 | 2005-10-20 | Parsons Xuejun H | Defined media for stem cell culture |
US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
US20080241107A1 (en) | 2004-01-23 | 2008-10-02 | Copland Iii John A | Methods and Compositions For Preparing Pancreatic Insulin Secreting Cells |
US20070298453A1 (en) | 2004-02-12 | 2007-12-27 | University Of Newcastle Upon Tyne | Stem Cells |
JP4901471B2 (ja) | 2004-02-19 | 2012-03-21 | 国立大学法人京都大学 | 体細胞核初期化物質のスクリーニング方法 |
CA2581424A1 (en) | 2004-03-09 | 2005-09-22 | Gang Xu | Methods for generating insulin-producing cells |
WO2005086845A2 (en) | 2004-03-10 | 2005-09-22 | Regents Of The University Of California | Compositions and methods for growth of embryonic stem cells |
KR101178786B1 (ko) | 2004-03-23 | 2012-09-07 | 다이이찌 산쿄 가부시키가이샤 | 다능성 줄기세포의 증식 방법 |
WO2005097980A2 (en) | 2004-03-26 | 2005-10-20 | Geron Corporation | New protocols for making hepatocytes from embryonic stem cells |
EP1730268A2 (en) | 2004-04-01 | 2006-12-13 | Wisconsin Alumni Research Foundation | Differentiation of stem cells to endoderm and pancreatic lineage |
EP1740612B1 (en) | 2004-04-27 | 2019-08-07 | Viacyte, Inc. | Pdx1 expressing endoderm |
WO2006016999A1 (en) | 2004-07-09 | 2006-02-16 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
CA2576872C (en) | 2004-08-13 | 2013-11-12 | University Of Georgia Research Foundation, Inc. | Compositions and methods for self-renewal and differentiation in human embryonic stem cells |
US20080268533A1 (en) | 2004-08-25 | 2008-10-30 | University Of Georgia Research Foundation, Inc. | Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells |
DE102004043256B4 (de) | 2004-09-07 | 2013-09-19 | Rheinische Friedrich-Wilhelms-Universität Bonn | Skalierbarer Prozess zur Kultivierung undifferenzierter Stammzellen in Suspension |
KR20070058584A (ko) | 2004-09-08 | 2007-06-08 | 위스콘신 얼럼나이 리서어치 화운데이션 | 인간 배아 줄기 세포의 배양 |
WO2006029197A1 (en) | 2004-09-08 | 2006-03-16 | Wisconsin Alumni Research Foundation | Medium and culture of embryonic stem cells |
GB2437689B (en) | 2005-01-28 | 2009-10-28 | Novathera Ltd | Culture and screening methods |
AU2006210955A1 (en) | 2005-01-31 | 2006-08-10 | Es Cell International Pte Ltd. | Directed differentiation of embryonic stem cells and uses thereof |
WO2006088867A2 (en) | 2005-02-15 | 2006-08-24 | Medistem Laboratories, Incorporated | Method for expansion of stem cells |
JP5265204B2 (ja) | 2005-03-04 | 2013-08-14 | ライフスキャン・インコーポレイテッド | 成人膵臓由来間質細胞 |
GB0505970D0 (en) | 2005-03-23 | 2005-04-27 | Univ Edinburgh | Culture medium containing kinase inhibitor, and uses thereof |
CN100425694C (zh) | 2005-04-15 | 2008-10-15 | 北京大学 | 诱导胚胎干细胞向胰腺细胞分化的方法 |
US7998938B2 (en) | 2005-04-15 | 2011-08-16 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
WO2006114098A2 (en) | 2005-04-26 | 2006-11-02 | Aarhus Universitet | Biocompatible material for surgical implants and cell guiding tissue culture surfaces |
JP5092124B2 (ja) | 2005-05-24 | 2012-12-05 | 国立大学法人 熊本大学 | Es細胞の分化誘導方法 |
AU2006202209B2 (en) | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
KR20080024194A (ko) | 2005-06-10 | 2008-03-17 | 아이알엠 엘엘씨 | 배아 줄기 세포의 다능성을 유지하는 화합물 |
WO2006138433A2 (en) | 2005-06-14 | 2006-12-28 | The Regents Of The University Of California | Induction of cell differentiation by class i bhlh polypeptides |
EP1931764A1 (en) | 2005-06-21 | 2008-06-18 | GE Healthcare Bio-Sciences AB | Method for cell culture |
US9074181B2 (en) | 2005-06-22 | 2015-07-07 | Asterias Biotherapeutics, Inc. | Suspension culture of human embryonic stem cells |
EA017545B1 (ru) | 2005-06-30 | 2013-01-30 | Янссен Фармацевтика Н.В. | Циклические анилино-пиридинотриазины в качестве ингибиторов gsk-3 |
DE102005031532A1 (de) * | 2005-07-01 | 2007-01-04 | Cytonet Gmbh & Co. Kg | Lagermedium für Zellen |
GB2443370A (en) | 2005-07-29 | 2008-04-30 | Australian Stem Cell Ct Ltd | Compositions and methods for growth of pluripotent cells |
WO2007016485A2 (en) | 2005-07-29 | 2007-02-08 | Athersys, Inc. | Use of a gsk-3 inhibitor to maintain potency of cultured cells |
WO2007025234A2 (en) | 2005-08-26 | 2007-03-01 | The Trustees Of Columbia University In The City Of New York | Generation of pancreatic endocrine cells from primary duct cell cultures and methods of use for treatment of diabetes |
SG177946A1 (en) | 2005-08-29 | 2012-02-28 | Technion Res & Dev Foundation | Media for culturing stem cells |
JP2009506769A (ja) | 2005-09-02 | 2009-02-19 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 間充織幹細胞誘導方法 |
US9422521B2 (en) | 2005-09-12 | 2016-08-23 | Es Cell International Pte Ltd. | Differentiation of pluripotent stem cells with a kinase inhibitor or PGI2 |
EP1941032A2 (en) | 2005-10-14 | 2008-07-09 | Regents Of The University Of Minnesota | Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype |
US7732202B2 (en) | 2005-10-21 | 2010-06-08 | International Stem Cell Corporation | Oxygen tension for the parthenogenic activation of human oocytes for the production of human embryonic stem cells |
AU2006305879B2 (en) | 2005-10-27 | 2012-05-10 | Viacyte, Inc. | PDX1-expressing dorsal and ventral foregut endoderm |
CN103113463B (zh) | 2005-12-13 | 2015-02-18 | 国立大学法人京都大学 | 核重新编程因子 |
WO2007082963A1 (es) | 2006-01-18 | 2007-07-26 | Fundación Instituto Valenciano De Infertilidad | Líneas de células madre embrionarias humanas y métodos para usar las mismas |
SG170021A1 (en) | 2006-02-23 | 2011-04-29 | Novocell Inc | Compositions and methods useful for culturing differentiable cells |
US7695965B2 (en) | 2006-03-02 | 2010-04-13 | Cythera, Inc. | Methods of producing pancreatic hormones |
SG10201405380QA (en) | 2006-03-02 | 2014-10-30 | Cythera Inc | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
AU2007244675A1 (en) | 2006-04-28 | 2007-11-08 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
JP5288209B6 (ja) | 2006-05-02 | 2018-06-27 | ウイスコンシン アラムニ リサーチ ファンデーション | 幹細胞の内胚葉細胞および膵臓系列細胞への分化方法 |
US8685730B2 (en) | 2006-05-02 | 2014-04-01 | Wisconsin Alumni Research Foundation | Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage |
WO2007136673A2 (en) | 2006-05-19 | 2007-11-29 | Medistem Laboratories, Inc. | Treatment of disc degenerative disease and compositions for same |
WO2007139929A2 (en) | 2006-05-25 | 2007-12-06 | The Burnham Institute For Medical Research | Methods for culture and production of single cell populations of human embryonic stem cells |
CN101541953A (zh) | 2006-06-02 | 2009-09-23 | 佐治亚大学研究基金会 | 通过从人胚胎干细胞获得的定形内胚层细胞的分化得到胰和肝内胚层细胞及组织 |
AU2007254766A1 (en) | 2006-06-02 | 2007-12-13 | University Of Georgia Research Foundation, Inc. | Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems |
WO2007149182A2 (en) | 2006-06-19 | 2007-12-27 | Geron Corporation | Differentiation and enrichment of islet-like cells from human pluripotent stem cells |
CN100494359C (zh) | 2006-06-23 | 2009-06-03 | 中日友好医院 | 神经干细胞三维立体培养体外扩增的方法 |
ES2610812T3 (es) | 2006-06-26 | 2017-05-03 | Lifescan, Inc. | Cultivo de células madre pluripotentes |
US20080003676A1 (en) | 2006-06-26 | 2008-01-03 | Millipore Corporation | Growth of embryonic stem cells |
AU2007270069B2 (en) | 2006-07-06 | 2013-05-16 | Es Cell International Pte Ltd | Method for stem cell culture and cells derived therefrom |
WO2008013664A2 (en) | 2006-07-26 | 2008-01-31 | Cythera, Inc. | Methods of producing pancreatic hormones |
ES2704401T3 (es) | 2006-08-02 | 2019-03-18 | Technion Res & Dev Foundation | Métodos de expansión de células madre embrionarias en un cultivo en suspensión |
KR101331510B1 (ko) | 2006-08-30 | 2013-11-20 | 재단법인서울대학교산학협력재단 | 저농도의 포도당을 함유하는 인간 배아줄기세포용 배지조성물 및 이를 이용한 인간 배아 줄기세포로부터 인슐린생산 세포 또는 세포괴로 분화시키는 방법, 그리고그로부터 유도된 인슐린 생산 세포 또는 세포괴 |
JP2008099662A (ja) * | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
WO2008039521A2 (en) | 2006-09-26 | 2008-04-03 | Nmt Medical, Inc. | Method for modifying a medical implant surface for promoting tissue growth |
CA2667053C (en) | 2006-10-17 | 2015-04-28 | Stiefel Laboratories, Inc. | Talarazole metabolites |
US20100323442A1 (en) | 2006-10-17 | 2010-12-23 | Emmanuel Edward Baetge | Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells |
CA2666789C (en) | 2006-10-18 | 2016-11-22 | Yong Zhao | Embryonic-like stem cells derived from adult human peripheral blood and methods of use |
WO2008056779A1 (fr) | 2006-11-09 | 2008-05-15 | Japan As Represented By The President Of International Medical Center Of Japan | Procédé destiné à la culture et au passage d'une cellule souche embryonnaire de primate, et procédé destiné à induire la différenciation de la cellule souche embryonnaire |
US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
TW200836749A (en) | 2007-01-09 | 2008-09-16 | Vioquest Pharmaceuticals Inc | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
EP2126045A4 (en) | 2007-01-30 | 2010-05-26 | Univ Georgia | EARLY MESODERM CELLS, STABLE POPULATION OF MESENDODERM CELLS WITH THE ABILITY TO GENERATE ENDODERM AND MESODERM CELL LINES AND MULTIPOTENTIAL MIGRATION CELLS |
GB0703188D0 (en) | 2007-02-19 | 2007-03-28 | Roger Land Building | Large scale production of stem cells |
US20090053182A1 (en) | 2007-05-25 | 2009-02-26 | Medistem Laboratories, Inc. | Endometrial stem cells and methods of making and using same |
WO2009006422A1 (en) | 2007-06-29 | 2009-01-08 | Stem Cell Products, Inc. | Automated method and apparatus for embryonic stem cell culture |
WO2009006399A1 (en) | 2007-07-01 | 2009-01-08 | Lifescan | Single pluripotent stem cell culture |
US20100255580A1 (en) | 2007-07-18 | 2010-10-07 | Lifesccan, Inc. | Differentiation of Human Embryonic Stem Cells |
CN101952415B (zh) | 2007-07-31 | 2017-06-27 | 生命扫描有限公司 | 人胚胎干细胞的分化 |
CN102317443B (zh) | 2007-07-31 | 2018-09-14 | 生命扫描有限公司 | 用人饲养细胞进行的多能干细胞分化 |
AU2008291930B2 (en) | 2007-08-24 | 2014-04-17 | Slotervaart Participaties Bv | Compositions for the treatment of neoplastic diseases |
WO2009061442A1 (en) | 2007-11-06 | 2009-05-14 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells |
CA2954431C (en) | 2007-11-27 | 2021-08-24 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic cells |
GB0800524D0 (en) * | 2008-01-14 | 2008-02-20 | Univ Brighton | Cell culture system |
SG154367A1 (en) | 2008-01-31 | 2009-08-28 | Es Cell Int Pte Ltd | Method of differentiating stem cells |
WO2009096049A1 (ja) | 2008-02-01 | 2009-08-06 | Kyoto University | 人工多能性幹細胞由来分化細胞 |
EP2250252A2 (en) | 2008-02-11 | 2010-11-17 | Cambridge Enterprise Limited | Improved reprogramming of mammalian cells, and the cells obtained |
US10066203B2 (en) | 2008-02-21 | 2018-09-04 | Janssen Biotech Inc. | Methods, surface modified plates and compositions for cell attachment, cultivation and detachment |
JPWO2009110215A1 (ja) | 2008-03-03 | 2011-07-14 | 独立行政法人科学技術振興機構 | 繊毛細胞の分化誘導方法 |
EP2271747B1 (en) * | 2008-03-17 | 2016-09-07 | Agency for Science, Technology And Research | Microcarriers for pluripotent stem cell culture |
RU2359030C1 (ru) | 2008-03-19 | 2009-06-20 | Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" | Способ получения эндотелиальных клеток из эмбриональных стволовых клеток человека (варианты) |
WO2009131568A1 (en) | 2008-04-21 | 2009-10-29 | Cythera, Inc. | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
US8338170B2 (en) | 2008-04-21 | 2012-12-25 | Viacyte, Inc. | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
US8728812B2 (en) | 2008-04-22 | 2014-05-20 | President And Fellows Of Harvard College | Compositions and methods for promoting the generation of PDX1+ pancreatic cells |
US7939322B2 (en) | 2008-04-24 | 2011-05-10 | Centocor Ortho Biotech Inc. | Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm |
US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
US20090298178A1 (en) | 2008-06-03 | 2009-12-03 | D Amour Kevin Allen | Growth factors for production of definitive endoderm |
DK2297319T3 (en) | 2008-06-03 | 2015-10-19 | Viacyte Inc | GROWTH FACTORS FOR PREPARING DEFINITIVE ENDODERM |
DE102008032236A1 (de) | 2008-06-30 | 2010-04-01 | Eberhard-Karls-Universität Tübingen | Isolierung und/oder Identifizierung von Stammzellen mit adipozytärem, chondrozytärem und pankreatischem Differenzierungspotential |
RU2533805C2 (ru) * | 2008-06-30 | 2014-11-20 | Сентокор Орто Байотек Инк. | Дифференцирование плюрипотентных стволовых клеток, представляющих собой линию клеток человека |
US20100028307A1 (en) | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
WO2010022395A2 (en) | 2008-08-22 | 2010-02-25 | President And Fellows Of Harvard College | Methods of reprogramming cells |
SG160248A1 (en) * | 2008-09-18 | 2010-04-29 | Agency Science Tech & Res | Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells |
WO2010051223A1 (en) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
ES2727950T3 (es) | 2008-10-31 | 2019-10-21 | Janssen Biotech Inc | Diferenciación de células madre embrionarias humanas en linaje endocrino pancreático |
US8895300B2 (en) * | 2008-11-04 | 2014-11-25 | Viacyte, Inc. | Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof |
US8008075B2 (en) | 2008-11-04 | 2011-08-30 | Viacyte, Inc. | Stem cell aggregate suspension compositions and methods of differentiation thereof |
EP3550012A1 (en) | 2008-11-04 | 2019-10-09 | ViaCyte, Inc. | Stem cell aggregate suspension compositions and methods for differentiation thereof |
WO2010057039A2 (en) | 2008-11-14 | 2010-05-20 | Cythera, Inc. | Encapsulation of pancreatic cells derived from human pluripotent stem cells |
WO2010059775A1 (en) | 2008-11-20 | 2010-05-27 | Centocor Ortho Biotech Inc. | Pluripotent stem cell culture on micro-carriers |
JP5604766B2 (ja) | 2008-12-05 | 2014-10-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 多能性細胞の神経分化のための方法および培地 |
GB0911060D0 (en) * | 2009-06-26 | 2009-08-12 | Ge Healthcare Uk Ltd | Methods for predicting the toxicity of a chemical |
CA2768720C (en) | 2009-07-20 | 2018-12-18 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
RU2579278C2 (ru) | 2009-07-20 | 2016-04-10 | Янссен Байотек, Инк. | Популяция панкреатических эндокринных клеток-предшественников для снижения концентрации глюкозы в крови и способ дифференцировки панкреатических эндодермальных клеток |
RU2540021C2 (ru) | 2009-07-20 | 2015-01-27 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека |
KR101755214B1 (ko) | 2009-08-12 | 2017-07-07 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 만능줄기세포의 신경전구세포로의 분화 유도 방법 |
US20110104805A1 (en) | 2009-10-29 | 2011-05-05 | Centocor Ortho Biotech Inc. | Pluripotent Stem Cells |
CA3174901A1 (en) | 2009-11-12 | 2011-05-19 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
FI20096288A0 (fi) | 2009-12-04 | 2009-12-04 | Kristiina Rajala | Formulations and methods for culturing stem cells |
CA2784425A1 (en) * | 2009-12-23 | 2011-06-30 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
MX343786B (es) | 2009-12-23 | 2016-11-22 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas. |
JP5762979B2 (ja) | 2009-12-29 | 2015-08-12 | 武田薬品工業株式会社 | 膵ホルモン産生細胞の製造法 |
CN102858958A (zh) | 2010-02-03 | 2013-01-02 | 日本国立癌症研究中心 | 诱导肝干细胞及其制造方法、以及该细胞的用途 |
SG183400A1 (en) | 2010-03-02 | 2012-09-27 | Univ Singapore | Culture additives to boost stem cell proliferation and differentiation response |
CN102959076B (zh) | 2010-03-31 | 2015-09-16 | 斯克里普斯研究所 | 重编程细胞 |
CN103068970A (zh) | 2010-04-25 | 2013-04-24 | 西奈山医学院 | 来自多能细胞的前部前肠内胚层的形成 |
WO2011143299A2 (en) | 2010-05-12 | 2011-11-17 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
JP5936134B2 (ja) | 2010-06-15 | 2016-06-15 | 国立大学法人京都大学 | ヒト人工多能性幹細胞の選択方法 |
WO2011160066A1 (en) * | 2010-06-17 | 2011-12-22 | Regents Of The University Of Minnesota | Production of insulin producing cells |
BR122020000909B1 (pt) | 2010-08-05 | 2021-02-23 | Wisconsin Alumni Research Foundation | Método para derivar uma célula tronco pluripotente induzida (ips)humana sob condições definidas |
PL2611907T3 (pl) | 2010-08-31 | 2016-11-30 | Różnicowanie pluripotencjalnych komórek macierzystych | |
US9528090B2 (en) * | 2010-08-31 | 2016-12-27 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
MY177150A (en) | 2011-02-28 | 2020-09-08 | Stempeutics Res Malaysia Sdn Bhd | Isolation and expansion of adult stem cells, their therapeutic composition and uses thereof |
WO2012170853A1 (en) * | 2011-06-10 | 2012-12-13 | Wisconsin Alumni Research Foundation ("Warf") | Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage |
US20130274184A1 (en) | 2011-10-11 | 2013-10-17 | The Trustees Of Columbia University In The City Of New York | Er stress relievers in beta cell protection |
US8951798B2 (en) | 2011-10-13 | 2015-02-10 | Wisconsin Alumni Research Foundation | Generation of cardiomyocytes from human pluripotent stem cells |
WO2013055397A1 (en) | 2011-10-14 | 2013-04-18 | Children's Medical Center Corporation | Inhibition and enhancement of reprogramming by chromatin modifying enzymes |
CN105143446B (zh) | 2011-12-22 | 2020-11-03 | 詹森生物科技公司 | 人胚胎干细胞分化成单一激素胰岛素阳性细胞 |
US10519422B2 (en) | 2012-02-29 | 2019-12-31 | Riken | Method of producing human retinal pigment epithelial cells |
ES2690118T3 (es) | 2012-06-08 | 2018-11-19 | Janssen Biotech, Inc. | Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas |
JP6470687B2 (ja) | 2012-09-03 | 2019-02-13 | ノヴォ ノルディスク アー/エス | 小分子を用いた多能性幹細胞からの膵臓内胚葉の作製 |
CN111394298A (zh) | 2012-12-31 | 2020-07-10 | 詹森生物科技公司 | 使用hb9调节子使人胚胎干细胞分化为胰腺内分泌细胞的方法 |
US8987471B2 (en) | 2013-02-14 | 2015-03-24 | Allergan, Inc. | Substituted dihydropyrazoles as sphingosine receptor modulators |
US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
TW201522637A (zh) | 2013-03-15 | 2015-06-16 | Jackson Lab | 非胚胎幹細胞之單離及其用途 |
-
2013
- 2013-12-30 US US13/998,974 patent/US10377989B2/en active Active
- 2013-12-30 MX MX2015008619A patent/MX2015008619A/es unknown
- 2013-12-30 RU RU2015131839A patent/RU2687379C2/ru active
- 2013-12-30 EP EP21212819.3A patent/EP4039798A1/en active Pending
- 2013-12-30 BR BR112015015714A patent/BR112015015714A2/pt not_active Application Discontinuation
- 2013-12-30 EP EP13868527.6A patent/EP2938722B1/en active Active
- 2013-12-30 WO PCT/US2013/078191 patent/WO2014106141A1/en active Application Filing
- 2013-12-30 DK DK13868527.6T patent/DK2938722T3/da active
- 2013-12-30 CA CA2896750A patent/CA2896750A1/en not_active Abandoned
- 2013-12-30 KR KR1020157020712A patent/KR20150103203A/ko active Search and Examination
- 2013-12-30 ES ES13868527T patent/ES2906998T3/es active Active
- 2013-12-30 SG SG10201709384SA patent/SG10201709384SA/en unknown
- 2013-12-30 JP JP2015550826A patent/JP6529440B2/ja active Active
- 2013-12-30 AU AU2013370228A patent/AU2013370228B2/en active Active
- 2013-12-30 RU RU2018108090A patent/RU2018108090A/ru not_active Application Discontinuation
- 2013-12-30 CN CN201380074012.2A patent/CN105705634A/zh active Pending
- 2013-12-30 SG SG11201505119UA patent/SG11201505119UA/en unknown
-
2015
- 2015-06-26 PH PH12015501477A patent/PH12015501477A1/en unknown
-
2016
- 2016-05-04 HK HK16105104.4A patent/HK1217727A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2013370228A1 (en) | 2015-07-09 |
BR112015015714A2 (pt) | 2017-07-11 |
US10377989B2 (en) | 2019-08-13 |
KR20150103203A (ko) | 2015-09-09 |
RU2018108090A (ru) | 2019-02-25 |
US20140242693A1 (en) | 2014-08-28 |
SG10201709384SA (en) | 2018-01-30 |
RU2015131839A (ru) | 2017-02-07 |
AU2013370228B2 (en) | 2018-10-18 |
CN105705634A (zh) | 2016-06-22 |
RU2687379C2 (ru) | 2019-05-13 |
EP2938722A4 (en) | 2017-03-22 |
ES2906998T3 (es) | 2022-04-21 |
PH12015501477A1 (en) | 2015-09-21 |
MX2015008619A (es) | 2016-01-12 |
CA2896750A1 (en) | 2014-07-03 |
JP2016504037A (ja) | 2016-02-12 |
HK1217727A1 (zh) | 2017-01-20 |
EP2938722B1 (en) | 2021-12-08 |
SG11201505119UA (en) | 2015-07-30 |
EP4039798A1 (en) | 2022-08-10 |
WO2014106141A1 (en) | 2014-07-03 |
EP2938722A1 (en) | 2015-11-04 |
DK2938722T3 (da) | 2022-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6529440B2 (ja) | 膵内分泌細胞への分化のためのヒト多能性細胞の懸濁及びクラスタリング | |
RU2689710C2 (ru) | Суспендирование и кластеризация плюрипотентных стволовых клеток человека с целью их дифференцировки в панкреатические эндокринные клетки | |
JP6800854B2 (ja) | 多能性幹細胞の懸濁培養 | |
US10370644B2 (en) | Method for making human pluripotent suspension cultures and cells derived therefrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161227 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171017 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180417 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20180417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180904 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190507 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190514 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6529440 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |